LONDON (Reuters) – Lung cancer can lie dormant for more than 20 years before turning deadly, helping explain why a disease that kills more than 1.5 million a year worldwide is so persistent and difficult to treat, scientists said on Thursday.
Two papers detailing the evolution of lung cancer reveal how after an initial disease-causing genetic fault — often due to smoking — tumor cells quietly develop numerous new mutations, making different parts of the same tumor genetically unique.
STOCKHOLM/LONDON (Reuters) – A German and two American scientists won the 2014 Nobel Prize for Chemistry on Wednesday for smashing the size barrier in optical microscopes, allowing researchers to see individual molecules inside living cells.
U.S. citizens Eric Betzig and William Moerner and Germany’s Stefan Hell won the prize for using fluorescence to take microscopes to a new level, making it possible to study things like the creation of synapses between brain cells in real time.
LONDON, Oct 8 (Reuters) – A pioneering cannabis drug
developed by British firm GW Pharmaceuticals for
treating spasticity in multiple sclerosis has been rejected as
not cost-effective in the company’s home market.
The National Institute for Health and Care Excellence
(NICE), which determines if medicines are worth using on
England’s state health service, said on Wednesday the modest
benefits and high cost of Sativex did not justify its use.
LONDON (Reuters) – Drugmaker GlaxoSmithKline, which was slapped with a record $489 million (304.26 million pound) fine for corruption in China last month, said on Tuesday it was looking into allegations of corruption in the United Arab Emirates.
Britain’s biggest pharmaceuticals group confirmed the investigation following allegations of improper payments set out in a whistleblower’s email sent to its top management on Monday. The email, purporting to be from a GSK sales manager in the Gulf state, was seen by Reuters.